ENGRAIL THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.engrail.com
Clinical Trials
9
Active:2
Completed:4
Trial Phases
3 Phases
Phase 1:3
Phase 2:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (42.9%)Phase 2
3 (42.9%)Not Applicable
1 (14.3%)A Dose-Response Safety Study of ENX-102 in Patients With GAD
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Engrail Therapeutics INC
- Target Recruit Count
- 36
- Registration Number
- NCT06653296
- Locations
- 🇬🇧
MAC Clinical Research, Manchester, United Kingdom
ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Phase 2
Recruiting
- Conditions
- Generalized Anxiety Disorder
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Engrail Therapeutics INC
- Target Recruit Count
- 200
- Registration Number
- NCT05749055
ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Engrail Therapeutics INC
- Registration Number
- NCT05481905
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center, Downey, California, United States
News
No news found